Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.
Irina TsibulakStephan PolterauerAlexander ReinthallerChristian SchauerJürg BergerChristian MarthPublished in: Wiener klinische Wochenschrift (2022)
The routine use of front-line bevacizumab for advanced ovarian cancer is associated with high efficacy comparable with that obtained in randomized phase III clinical trials; however, hypertension and proteinuria were reported significantly more often in our Austria-based real-world population.